Japan’s hip reconstruction market to be valued at $570m by 2036.

The country accounted for around 30% of the APAC market in 2024.

Japan’s hip reconstruction market is expected to be valued at $570m by 2036, according to GlobalData.

The country accounted for around 30% of the Asia-Pacific hip reconstruction market in 2024, driven by the growing disease burden and rising demand for surgical treatment.

“Adopting advanced technologies to prevent postoperative infections is critical to lower patient morbidity, contain healthcare costs, and improve overall patient outcomes,” said Priyanka Chakraborty, Medical Devices Analyst at GlobalData.

The Pharmaceutical and Medical Devices Agency in Japan has recently approved iTaperloc Complete and iG7 Hip System orthopaedic implants by Zimmer Biomet Holdings.

The new implants incorporate Iodine technology, which combines established clinical performance with advanced infection-prevention features to offer safer alternatives to conventional implants.

“Strong infrastructure and acceptance of novel technology will also pave the way for pipeline innovations and new investments,” Chakraborty added.